GlobeNewswire: Innovus Pharmaceuticals, Inc. Contains the last 10 of 55 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T02:34:08ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/06/04/1516504/0/en/Innovus-Pharma-Announces-the-Approval-of-its-Product-ProstaGorx-in-Canada-for-Benign-Prostate-Hyperplasia-BPH.html?f=22&fvtc=4&fvtv=13962Innovus Pharma Announces the Approval of its Product ProstaGorx in Canada for Benign Prostate Hyperplasia ("BPH")2018-06-04T18:46:08Z<![CDATA[ProstaGorx is the Ninth Innovus Pharma Product Approved in Canada to Date]]>https://www.globenewswire.com/news-release/2014/10/02/670239/10100995/en/Innovus-Pharma-Announces-Podium-Presentation-at-the-World-Meeting-of-Sexual-Medicine-Discussing-the-Clinical-Efficacy-of-Zestra-R-in-Cancer-Patients.html?f=22&fvtc=4&fvtv=13962Innovus Pharma Announces Podium Presentation at the World Meeting of Sexual Medicine, Discussing the Clinical Efficacy of Zestra(R) in Cancer Patients2014-10-02T10:00:00Z<![CDATA[SAN DIEGO, Oct. 2, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCQB:INNV) announced today the selection of an oral podium presentation of Zestra®, its clinically proven topical product to increase female sexual arousal and desire entitled, "Female Arousal and Orgasmic Complaints in a Diverse Cancer Population Treated with Zestra®: A Topical Applied Blend of Oils", at the World Meeting on Sexual Medicine, which will take place in Sao Paulo, Brazil, from October 8 to 12, 2014. The podium presentation will be given by Dr. Michael Krychman and is scheduled under The Arousal and Desire session on Thursday, October 9, 11:30 am - 12:30 pm. Innovus will also exhibit two posters. The moderated poster entitled "Treatment Paradigm for Women with Arousal and Orgasmic Complaints", under the Women's Sexual Medicine session is scheduled for presentation on Saturday, October 11, 14:00 - 15:30 hrs. The non-moderated poster presentation entitled "Female Arousal and Orgasmic Complaints in a Diverse Female Population with Multiple Medical Issues Treated with Zestra®" will be exhibited digitally for the duration of the meeting from October 8 to 12]]>https://www.globenewswire.com/news-release/2014/09/24/668096/10099840/en/Innovus-Pharma-Signs-License-Agreement-With-Sothema-Laboratories-for-Zestra-R-and-Zestra-Glide-R-in-the-Middle-East-Excluding-Lebanon-and-Israel-North-Africa-and-West-Africa.html?f=22&fvtc=4&fvtv=13962Innovus Pharma Signs License Agreement With Sothema Laboratories for Zestra(R) and Zestra Glide(R) in the Middle East (Excluding Lebanon and Israel), North Africa and West Africa2014-09-24T10:15:00Z<![CDATA[Innovus Eligible to Receive Upfront and Up to $171.25 Million U.S. in Sales Milestone Payments Plus Transfer Price SAN DIEGO, Sept. 24, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCBB:INNV) announced today it has entered into an exclusive license agreement with Sothema Laboratories, SARL, a Moroccan company (SOT.CSE) ("Sothema") under which Innovus Pharma granted to Sothema an exclusive license to market and sell Innovus Pharma's topical treatment for Female Sexual Desire Disorder ("FSDD"), Zestra® and its high viscosity water-based lubricant Zestra Glide® in the North African countries of Egypt, Morocco, Algeria, Tunisia and Libya, the Middle Eastern countries of Iraq, Jordan, Saudi Arabia and the United Arab Emirates (excluding Lebanon and Israel) and the West African countries of Benin, Burkina Faso, Cape Verde, Gambia, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone and Togo (collectively the "Territory"). Under the agreement, Innovus will receive an upfront payment and is eligible to receive up to approximately $171.25 million U.S. dollars upon and subject to the achievement of sales milestones based on cumulative supplied units of the licensed products in the Territory plus a pre-negotiated transfer price per unit.]]>https://www.globenewswire.com/news-release/2014/09/22/667433/10099446/en/Innovus-Pharma-Signs-License-Agreement-With-Orimed-Pharma-for-Zestra-R-EjectDelay-TM-Sensum-TM-and-Zestra-Glide-R-in-Canada.html?f=22&fvtc=4&fvtv=13962Innovus Pharma Signs License Agreement With Orimed Pharma for Zestra(R), EjectDelay(TM), Sensum+(TM) and Zestra Glide(R) in Canada2014-09-22T10:15:00Z<![CDATA[Innovus Eligible to Receive Up to $94.5 Million CAD in Upfront and Sales Milestone Payments Plus Double-Digit Tiered Royalties SAN DIEGO, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCBB:INNV) announced today it has entered into a license agreement with Orimed Pharma ("Orimed"), an affiliate of JAMP Pharma, under which Innovus Pharma granted to Orimed an exclusive license to market and sell Innovus Pharma's topical treatment for Female Sexual Desire Disorder("FSDD"), Zestra®, its topical treatment for premature ejaculation, EjectDelay™, its product Sensum+™ (previously called CIRCUMSerum™) to increase penile sensitivity and its high viscosity water based lubricant, Zestra Glide® in Canada. Under the agreement, Innovus will receive an upfront payment and is eligible to receive up to approximately $94.5 million Canadian dollars upon and subject to the achievement of sales milestones based on cumulative gross sales in Canada by Orimed plus certain double-digit tiered royalties based on Orimed's cumulative net sales in Canada.]]>https://www.globenewswire.com/news-release/2014/09/18/666876/10099144/en/Innovus-Pharma-Signs-Exclusive-Marketing-Sales-and-Distribution-Agreement-With-Tramorgan-Limited-to-Market-and-Distribute-Sensum-TM-in-the-United-Kingdom.html?f=22&fvtc=4&fvtv=13962Innovus Pharma Signs Exclusive Marketing Sales and Distribution Agreement With Tramorgan Limited to Market and Distribute Sensum+(TM) in the United Kingdom2014-09-18T10:15:00Z<![CDATA[-Innovus Pharma Eligible to Receive Up to $44 Million in Sales Milestone Payments Based on Tramorgan's Cumulative Sales Plus 50% Royalties on Its Net Sales SAN DIEGO, Sept. 18, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCQB:INNV) announced today that it has entered into an exclusive marketing and distribution agreement with Tramorgan Limited, a British company ("Tramorgan") under which Innovus Pharma has granted to Tramorgan an exclusive marketing sales and distribution right to market and sell Innovus Pharma's topical consumer care product to increase penile sensitivity, Sensum+™ in the United Kingdom ("UK"). The agreement has an initial term of December 31, 2016 and can be extended thereafter for a twenty-four month period if Tramorgan has reached certain aggregate sales milestones. Pursuant to the agreement, Innovus Pharma is eligible to receive (a) up to $44 million dollars in sales milestone payments based on Tramorgan's attainment of certain levels of cumulative gross sales amounts plus (b) fifty percent (50%) royalties based on Tramorgan's net sales after distribution costs in the UK. The product will be available in 10ml multi-dose dispenser and single use packets.]]>https://www.globenewswire.com/news-release/2014/09/08/664248/10097512/en/Innovus-Pharma-Expands-US-Distribution-by-Signing-a-Non-Exclusive-Sampling-and-Distribution-Agreement-With-Bulu-Box-R-for-Zestra-R-in-the-US.html?f=22&fvtc=4&fvtv=13962Innovus Pharma Expands US Distribution by Signing a Non-Exclusive Sampling and Distribution Agreement With Bulu Box(R) for Zestra(R) in the US2014-09-08T10:00:00Z<![CDATA[SAN DIEGO, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCQB:INNV), announced today it has entered into an non-exclusive sampling, marketing and distribution agreement with Bulu Box® ("Bulu Box") under which Bulu Box will add Zestra® as part of its monthly box to all current subscribers. In addition, Bulu Box will sell Zestra® 3 packettes box through its E-commerce platform in the US.]]>https://www.globenewswire.com/news-release/2014/09/04/663665/10097180/en/Innovus-Pharma-to-Present-at-the-2014-Aegis-Healthcare-Conference-in-Las-Vegas-NV-and-the-See-Thru-Equity-Fall-Microcap-Investor-Conference-in-New-York.html?f=22&fvtc=4&fvtv=13962Innovus Pharma to Present at the 2014 Aegis Healthcare Conference in Las Vegas, NV and the See Thru Equity Fall Microcap Investor Conference in New York2014-09-04T10:00:00Z<![CDATA[SAN DIEGO, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCBB:INNV) today announced that Dr. Bassam Damaj, President & CEO of the Company is scheduled to present at the 2014 Aegis Healthcare Conference to be held September 10-13, 2014 at The Encore at Wynn Las Vegas. The Company's presentation will be on Friday, September 12th at 8:00 a.m. PDT.]]>https://www.globenewswire.com/news-release/2014/08/28/661932/10096366/en/Innovus-Pharma-Signs-Exclusive-Marketing-and-Distribution-Agreement-With-DanaLife-ApS-to-Market-and-Distribute-Zestra-R-for-Alternative-Markets.html?f=22&fvtc=4&fvtv=13962Innovus Pharma Signs Exclusive Marketing and Distribution Agreement With DanaLife ApS to Market and Distribute Zestra(R) for Alternative Markets2014-08-28T10:00:00Z<![CDATA[SAN DIEGO, Aug. 28, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCQB:INNV) announced today it has entered into an exclusive marketing and distribution agreement with DanaLife ApS based in Denmark ("DanaLife") under which Innovus Pharma has granted to DanaLife an exclusive 18 month worldwide distribution right ( excluding Canada) , to market and sell Innovus Pharma's topical consumer care product to increase Female Sexual Arousal and Desire and Satisfaction, Zestra® for the alternative markets which excludes all medical and mainstream sales channels. The Company is in the process of negotiating commercial agreements with Pharmaceutical companies to promote the product in the medical and mainstream channels. Under the agreement the initial minimum orders are expected to be two hundred and fifty thousand US dollars. The terms of the agreement can be extended automatically by another 18 months if DanaLife meets certain minimum sales numbers.]]>https://www.globenewswire.com/news-release/2014/08/21/660339/10095572/en/Innovus-Announces-Formation-of-a-Global-Clinical-Advisory-Board-to-Support-the-Growth-of-Its-Product-Zestra-R.html?f=22&fvtc=4&fvtv=13962Innovus Announces Formation of a Global Clinical Advisory Board to Support the Growth of Its Product Zestra(R)2014-08-21T10:00:00Z<![CDATA[SAN DIEGO, Aug. 21, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or "Company") (www.innovuspharma.com) (OTCQB:INNV), announced today the formation of a Clinical Advisory Board made up of top key opinion leaders in the fields of gynecology and sexual health to support the continued growth of its Zestra]]>https://www.globenewswire.com/news-release/2014/08/15/658999/10094867/en/Innovus-Pharma-and-Consortia-Health-Initiate-a-Nationwide-Marketing-and-Sales-Campaign-to-U-S-Gynecologists-for-Zestra-R-Clinically-Proven-for-the-Enhancement-of-Female-Arousal-Des.html?f=22&fvtc=4&fvtv=13962Innovus Pharma and Consortia Health Initiate a Nationwide Marketing and Sales Campaign to U.S. Gynecologists for Zestra(R), Clinically Proven for the Enhancement of Female Arousal Desire and Satisfaction2014-08-15T10:00:00Z<![CDATA[SAN DIEGO, Aug. 15, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCBB:INNV) a leader in over-the-counter ("OTC") and consumer care products for men and women's sexual dysfunction and health products announced today that its U.S. sales and marketing partner, Consortia Health, began recently the detailing of its Zestra® product clinically proven to enhance arousal, desire and satisfaction in women to gynecologists in 13 states. Consortia's 25 member sales force is composed of sales representatives and nurse practitioners. The sales force currently covers over 50% of the US population in the following U.S. states: Pennsylvania, Michigan, Nevada, Texas, Florida, Louisiana, Georgia, New York, New Jersey, Colorado, Washington, Utah, California, North Carolina and Arizona.]]>